CCCC Q1 2020 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$239M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+74.6% YoY

Gross Profit

-$9M-139.3% margin

Operating Income

-$12M-181.0% margin

Net Income

-$12M-174.8% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

-17.0%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$116,000

Balance Sheet

Total Assets

$0

Total Liabilities

$0

Stockholders' Equity

-$968,000

Cash & Equivalents

-$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$4M	+74.6%
Gross Profit	-$9M	-$6M	-68.3%
Operating Income	-$12M	-$7M	-65.0%
Net Income	-$12M	-$9M	-31.0%